28 January 2021 
EMA/CHMP/622868/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Byfavo 
remimazolam 
On 28 January 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Byfavo, 
intended for procedural sedation. The applicant for this medicinal product is PAION Netherlands B.V. 
Byfavo will be available as a powder for solution for injection (20 mg). The active substance of Byfavo is 
remimazolam, an ultra-short acting benzodiazepine sedative (ATC code: N05CD14). 
The benefits with Byfavo are its ability to induce sedation during diagnostic or therapeutic procedures. 
The most common side effects are hypotension, hypoxia and bradycardia. 
The full indication is: “Remimazolam is indicated in adults for procedural sedation.” 
Byfavo should be administered by healthcare professionals experienced in sedation. 
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
